CurrentUnitedHealthcarePolicy CSO29KY.06

Cytological Examination of Breast Ductal Fluids (Ductal Lavage, Nipple Aspirate Fluid, Fiberoptic Ductoscopy) for Breast Cancer Screening/Diagnosis

State-specific (Kentucky) UnitedHealthcare medical policy addressing the use of cytological examination of breast ductal fluids (ductal lavage, nipple aspirate fluid, fiberoptic ductoscopy) for breast cancer screening, diagnosis, and as alternatives to guide surgery. The policy summarizes evidence, provides an applicability statement for Kentucky members, lists an applicable CPT unlisted code, and states these procedures are unproven and not medically necessary for screening/diagnosis or as surgical alternatives.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Ductal Fluids (Ductal Lavage, Nipple Aspirate Fluid, Fiberoptic Ductoscopy) for Breast Cancer Screening/Diagnosis

Policy CodePolicy CSO29KY.06

Change TypeSupporting Information Updated

Effective DateAugust 1, 2025

Next Review Date

Key ActionProviders should follow established breast cancer screening and diagnostic guidelines (e.g., NCCN) and not use ductal lavage, nipple aspirate fluid cytology, or fiberoptic ductoscopy for routine screening or diagnosis given insufficient evidence.

POLICY UPDATE CHANGES

Supporting Information Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

3Procedures declared not medically necessary

Kentucky onlyGeographic scope

Coverage Summary

This state-specific UnitedHealthcare medical policy (Kentucky) addresses the use of cytological examination of breast ductal fluids — including ductal lavage (DL), nipple aspirate fluid (NAF) collection/aspiration, and fiberoptic ductoscopy (FDS) — for breast cancer screening, diagnosis, and as alternatives to guide surgery. The policy stance is: Not medically necessary / Not covered for these procedures in the Kentucky population. It lists an applicable reference CPT code 19499 (Unlisted procedure, breast) and applies only to Kentucky members; providers should verify member-specific benefit plans and applicable laws.

Medical Necessity / Not Medically Necessary Criteria

Medically Necessary / Not Medically Necessary Criteria

The following procedures are considered unproven and not medically necessary for breast cancer screening, diagnosis, or as alternative tools to guide surgery:

ALL of the following

Breast ductal fluid aspiration and cytology is unproven and not medically necessary for breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy.
Breast ductal lavage is unproven and not medically necessary for breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy.
Fiberoptic ductoscopy, with or without ductal lavage, is unproven and not medically necessary for breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy.

Procedures Considered Unproven or Not Medically Necessary

Cytological assessment of breast ductal fluids (ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) is considered unproven and not medically necessary for breast cancer screening, diagnosis, or as alternative tools to guide surgery due to insufficient evidence of clinical benefit. Studies report low sensitivity and a high proportion of inadequate or inconclusive samples, and practice guidelines (NCCN) do not recommend routine use. There is no evidence that these techniques improve breast cancer mortality or clinical outcomes, and further longitudinal validation would be required to establish clinical utility.

Not Medically Necessary (operational representation)

The following procedures are considered unproven and not medically necessary for breast cancer screening, diagnosis, or as alternative tools to guide surgery:

Not Medically Necessary

Breast ductal fluid aspiration and cytology is unproven and not medically necessary for breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy.
Breast ductal lavage is unproven and not medically necessary for breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy.
Fiberoptic ductoscopy, with or without ductal lavage, is unproven and not medically necessary for breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy.

Provider Actions

Documentation Required

State applicability

This medical policy applies only to the state of Kentucky; providers should check member-specific benefit plans and federal/state/contractual requirements that govern coverage decisions.

Documentation Required

Use alternative recommended modalities

Providers should follow established breast cancer screening and diagnostic guidelines (for example, NCCN) and should not use ductal lavage, nipple aspirate fluid cytology, or fiberoptic ductoscopy for routine screening or diagnosis given insufficient evidence of efficacy and guideline recommendations.

Background and Evidence Summary

Investigations of cytologic examination of ductal fluids have shown important limitations: DL and NAF studies demonstrate low sensitivity for cancer detection and high rates of inadequate or inconclusive samples (for example, many NAF samples are inadequate for analysis). Multiple cohort and single-center studies report frequent benign or non-diagnostic results and poor predictive value for future cancer. Available evidence does not show that routine collection and cytologic analysis of ductal fluids leads to earlier detection that improves survival or other clinical outcomes.

Source	Key Finding
NCCN recommendation
Ductal lavage is not recommended; nipple smear cytology not routinely recommended for nipple discharge without palpable symptom (NCCN, 2025).
Systematic review (Jiwa 2021)
NAF cytology sensitivity poor; 38.9% of NAF samples inadequate for analysis; diagnostic accuracy limited.
Khan et al. 2004
Ductal lavage overall low sensitivity (reported 17%–79% depending on definition) with generally high specificity in some analyses (up to 100%); overall low sensitivity noted.
Waaijer et al. 2016
Ductoscopy pooled sensitivity 94% using 'any' definition but low specificity (47%); with 'suspicious' definition sensitivity 50% and specificity 83%.

Definitions

Ductal Lavage (DL)Invasive procedure that removes ductal fluid by inserting a microcatheter into breast ducts via the nipple to collect cells for cytology.

Nipple Aspirate Fluid (NAF)Fluid obtained noninvasively or via fine needle aspiration from the nipple used for cytologic or biomarker analysis.

Fiberoptic Ductoscopy (FDS)Endoscopic visualization of breast ducts using a very thin endoscope; may be performed with or without ductal lavage.